131 related articles for article (PubMed ID: 28429056)
1. Prognostic significance of supradiaphragmatic lymph nodes at initial presentation in patients with stage III high-grade serous ovarian cancer.
McIntosh LJ; O'Neill AC; Bhanusupriya S; Matalon SA; Van den Abbeele AD; Ramaiya NH; Shinagare AB
Abdom Radiol (NY); 2017 Oct; 42(10):2513-2520. PubMed ID: 28429056
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced epithelial ovarian cancer.
Kolev V; Mironov S; Mironov O; Ishill N; Moskowitz CS; Gardner GJ; Levine DA; Hricak H; Barakat RR; Chi DS
Int J Gynecol Cancer; 2010 Aug; 20(6):979-84. PubMed ID: 20683405
[TBL] [Abstract][Full Text] [Related]
3. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.
Ayhan A; Ozkan NT; Sarı ME; Celik H; Dede M; Akbayır Ö; Güngördük K; Şahin H; Haberal A; Güngör T; Arvas M; Meydanlı MM
J Gynecol Oncol; 2018 Jan; 29(1):e12. PubMed ID: 29185270
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.
Chung YS; Lee JY; Kim HS; Nam EJ; Kim SW; Kim YT
Yonsei Med J; 2018 Oct; 59(8):930-936. PubMed ID: 30187699
[TBL] [Abstract][Full Text] [Related]
6. Patterns and Prognostic Importance of Hepatic Involvement in Patients with Serous Ovarian Cancer: A Single-Institution Experience with 244 Patients.
O'Neill AC; Somarouthu B; Tirumani SH; Braschi-Amirfarzan M; Van den Abbeele AD; Ramaiya NH; Shinagare AB
Radiology; 2017 Jan; 282(1):160-170. PubMed ID: 27479640
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer.
Cybulska P; Hayes SA; Spirtos A; Rafizadeh MJ; Filippova OT; Leitao M; Zivanovic O; Sonoda Y; Mueller J; Lakhman Y; Long K; Chi DS
Int J Gynecol Cancer; 2019 Nov; 29(9):1377-1380. PubMed ID: 31575614
[TBL] [Abstract][Full Text] [Related]
8. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
[TBL] [Abstract][Full Text] [Related]
9. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
Feng Z; Wen H; Bi R; Duan Y; Yang W; Wu X
BMC Cancer; 2016 Jan; 16():43. PubMed ID: 26817451
[TBL] [Abstract][Full Text] [Related]
10. Metastatic patterns do not provide additional prognostic information for patients with FIGO stage IV high-grade serous ovarian cancer.
Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
J Surg Oncol; 2020 Aug; 122(2):315-319. PubMed ID: 32500598
[TBL] [Abstract][Full Text] [Related]
11. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.
Lee JY; Chung YS; Na K; Kim HM; Park CK; Nam EJ; Kim S; Kim SW; Kim YT; Kim HS
J Gynecol Oncol; 2017 Nov; 28(6):e73. PubMed ID: 28758379
[TBL] [Abstract][Full Text] [Related]
12. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
13. The significance of paracardiac lymph node enlargement in ovarian cancer.
Holloway BJ; Gore ME; A'Hern RP; Parsons C
Clin Radiol; 1997 Sep; 52(9):692-7. PubMed ID: 9313735
[TBL] [Abstract][Full Text] [Related]
14. Radiogenomics of High-Grade Serous Ovarian Cancer: Multireader Multi-Institutional Study from the Cancer Genome Atlas Ovarian Cancer Imaging Research Group.
Vargas HA; Huang EP; Lakhman Y; Ippolito JE; Bhosale P; Mellnick V; Shinagare AB; Anello M; Kirby J; Fevrier-Sullivan B; Freymann J; Jaffe CC; Sala E
Radiology; 2017 Nov; 285(2):482-492. PubMed ID: 28641043
[TBL] [Abstract][Full Text] [Related]
15. Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a Swedish Gynecologic Cancer Group (SweGCG) study.
Hjerpe E; Staf C; Dahm-Kähler P; Stålberg K; Bjurberg M; Holmberg E; Borgfeldt C; Tholander B; Hellman K; Kjølhede P; Högberg T; Rosenberg P; Åvall-Lundqvist E
Acta Oncol; 2018 Mar; 57(3):331-337. PubMed ID: 29130381
[TBL] [Abstract][Full Text] [Related]
16. High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes.
Nougaret S; Lakhman Y; Gönen M; Goldman DA; Miccò M; D'Anastasi M; Johnson SA; Juluru K; Arnold AG; Sosa RE; Soslow RA; Vargas HA; Hricak H; Kauff ND; Sala E
Radiology; 2017 Nov; 285(2):472-481. PubMed ID: 28628421
[TBL] [Abstract][Full Text] [Related]
17. Age is associated with prognosis in serous ovarian carcinoma.
Deng F; Xu X; Lv M; Ren B; Wang Y; Guo W; Feng J; Chen X
J Ovarian Res; 2017 Jun; 10(1):36. PubMed ID: 28606125
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of enlarged cardiophrenic lymph nodes in advanced ovarian cancer: Implications for survival.
Mert I; Kumar A; Sheedy SP; Weaver AL; McGree ME; Kim B; Cliby WA
Gynecol Oncol; 2018 Jan; 148(1):68-73. PubMed ID: 29129390
[TBL] [Abstract][Full Text] [Related]
19. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinical behavior between mucinous ovarian carcinoma with infiltrative and expansile invasion and high-grade serous ovarian carcinoma: a retrospective analysis.
Hada T; Miyamoto M; Ishibashi H; Matsuura H; Kakimoto S; Iwahashi H; Tsuda H; Takano M
Diagn Pathol; 2022 Jan; 17(1):12. PubMed ID: 35057833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
